Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study
Primary Purpose
Type1diabetes
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
4T Education and Care
Sponsored by
About this trial
This is an interventional supportive care trial for Type1diabetes
Eligibility Criteria
Inclusion Criteria:
(Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 1-21 years of age.
(NOTE: Investigators will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.)
- All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic
- Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic
- Individuals who agree to CGM data integration into the EMR for remote monitoring
- Age: six months to < 21 years of age
- Patient or guardian must own and operate an Apple compatible device (e.g. iPhone or iPod Touch) to allow for Dexcom app and Apple HealthKit integration and transmission of GluVue remote data monitoring [Dr Prahalad's LPCH Auxiliary Fund grant (in addition to the R18) has resources to support iPod Touch purchase for participants who do not have these.]
Exclusion Criteria:
- Diabetes diagnosis other than T1D
- Diagnosis of diabetes > one month prior to initial visit
- Individuals with the intention of obtaining diabetes care at another clinic
- Individuals who do not consent to CGM use, CGM data integration, remote monitoring
- Individuals > 21 years of age
Sites / Locations
- Franziska Katherine Bishop
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
T1D Patients
Arm Description
Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
Outcomes
Primary Outcome Measures
Change in rise of HbA1c
Rise in HbA1c (a measure of blood sugar levels over the previous 3 months) as a measurement of the effect of 4T education and care. Collected through a blood sample.
Secondary Outcome Measures
Change in CGM Benefits and Burden Scale
This tool measures the benefits and burden of Continuous Glucose Monitor (CGM) device use, and is reported by participants.
PERCEIVED BENEFITS OF CGM SCALE (BenCGM):
Below is a list of things people might think are good about wearing a CGM.
5 - Strongly agree 4 -Agree 3 - Neutral 2 - Disagree
1 - Strongly disagree
Change Diabetes Distress Scale
This measure is widely used to capture the psychological distress experienced in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Change in Diabetes Technology Attitude Scale
This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices, and is reported by participants.
Tool lists statement and participants reports how much they agree with the statement.
1 2 3 4 5 Strongly disagree Disagree Neutral Agree Strongly agree
Change in Parental Diabetes Distress Scale
The Parental Diabetes Distress Scale (PARENT-DDS) measure is widely used to capture the psychological distress experienced by parents in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Change in Promise Global Health Scale
This measure is widely used to capture general and overall health, and is reported by participants.
PROMISE GLOBAL HEALTH SCALES
5, Excellent | 4, Very Good | 3, Good | 2, Fair | 1, Poor
Change in Physical Activity, Youth Physical Activity Questionnaire (Y-PAQ)
Youth Physical Activity Questionnaire (Y-PAQ) is a measure used to determine overall physical activity in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Change in Physical Activity, International Physical Activity Questionnaire (IPAQ)
International Physical Activity Questionnaire (IPAQ) asks about physical activity and sedentary behavior in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Change in participant Hypoglycemic Fear Scale
People with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-II) measure captures those worries and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Change in parent Hypoglycemic Fear Scale
Parents of children with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-P) measure captures those worries and is reported by parents of participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Change in Self-Efficacy for Exercise Scale
Self-Efficacy for Exercise (SEE) Scale measures how confident people are in their ability to overcome barriers to exercise.
Total scale is calculated by summing the responses to each question. The scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Change in education exposure to safe exercise strategies
Percentage of participants attending at least one telehealth session and a measure of education exposure to safe exercise strategies
Full Information
NCT ID
NCT04336969
First Posted
April 3, 2020
Last Updated
December 5, 2022
Sponsor
Stanford University
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT04336969
Brief Title
Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study
Official Title
Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
June 18, 2020 (Actual)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
December 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The 4Ts program encompasses: Teamwork, Targets, Technology, and Tight Control. These methods will help patients better manage their condition of Type 1 Diabetes with improved patient reported outcomes.
Detailed Description
The goal of the 4T study is to implement proven methods and emerging diabetes technology into investigator's clinical practice to sustain tight glucose control from the onset of type 1 diabetes (T1D) and optimize patient reported and psychosocial outcomes. The investigators will define a program (4T - Teamwork, Targets, Technology, and Tight Control) translatable to Pediatric Diabetes clinics in the United States that reduces HbA1c and T1D burden and improves patient well-being.
Study Design: This is a prospective, open-label, pragmatic research study. Two related studies will be performed. In Study 2, a cohort of new onsets (160+) receiving the 4T new onset intervention designed to decrease the rise in HbA1c seen from 4 to 12 months but following a tapered remote monitoring schedule will be compared to internal (4T Pilot and 4T Study 1) and external contemporaneous controls (CMH and DPV).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1diabetes
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
T1D Patients
Arm Type
Other
Arm Description
Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
Intervention Type
Behavioral
Intervention Name(s)
4T Education and Care
Intervention Description
CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.
Primary Outcome Measure Information:
Title
Change in rise of HbA1c
Description
Rise in HbA1c (a measure of blood sugar levels over the previous 3 months) as a measurement of the effect of 4T education and care. Collected through a blood sample.
Time Frame
Baseline, 6 months and 12 months post-diagnosis
Secondary Outcome Measure Information:
Title
Change in CGM Benefits and Burden Scale
Description
This tool measures the benefits and burden of Continuous Glucose Monitor (CGM) device use, and is reported by participants.
PERCEIVED BENEFITS OF CGM SCALE (BenCGM):
Below is a list of things people might think are good about wearing a CGM.
5 - Strongly agree 4 -Agree 3 - Neutral 2 - Disagree
1 - Strongly disagree
Time Frame
Baseline, 3, 6, 9 and 12 months
Title
Change Diabetes Distress Scale
Description
This measure is widely used to capture the psychological distress experienced in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Time Frame
Baseline, 3, 6, 9 and 12 months
Title
Change in Diabetes Technology Attitude Scale
Description
This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices, and is reported by participants.
Tool lists statement and participants reports how much they agree with the statement.
1 2 3 4 5 Strongly disagree Disagree Neutral Agree Strongly agree
Time Frame
Baseline, 3, 6, 9 and 12 months
Title
Change in Parental Diabetes Distress Scale
Description
The Parental Diabetes Distress Scale (PARENT-DDS) measure is widely used to capture the psychological distress experienced by parents in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Time Frame
Baseline, 3, 6, 9 and 12 months
Title
Change in Promise Global Health Scale
Description
This measure is widely used to capture general and overall health, and is reported by participants.
PROMISE GLOBAL HEALTH SCALES
5, Excellent | 4, Very Good | 3, Good | 2, Fair | 1, Poor
Time Frame
Baseline, 3, 6, 9 and 12 months
Title
Change in Physical Activity, Youth Physical Activity Questionnaire (Y-PAQ)
Description
Youth Physical Activity Questionnaire (Y-PAQ) is a measure used to determine overall physical activity in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Time Frame
Baseline, 3, 6 and 9 months
Title
Change in Physical Activity, International Physical Activity Questionnaire (IPAQ)
Description
International Physical Activity Questionnaire (IPAQ) asks about physical activity and sedentary behavior in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Time Frame
Baseline, 3, 6 and 9 months
Title
Change in participant Hypoglycemic Fear Scale
Description
People with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-II) measure captures those worries and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Time Frame
Baseline, 3, 6 and 9 months
Title
Change in parent Hypoglycemic Fear Scale
Description
Parents of children with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-P) measure captures those worries and is reported by parents of participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Time Frame
Baseline, 3, 6 and 9 months
Title
Change in Self-Efficacy for Exercise Scale
Description
Self-Efficacy for Exercise (SEE) Scale measures how confident people are in their ability to overcome barriers to exercise.
Total scale is calculated by summing the responses to each question. The scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Time Frame
Baseline, 3, 6, and 9 months
Title
Change in education exposure to safe exercise strategies
Description
Percentage of participants attending at least one telehealth session and a measure of education exposure to safe exercise strategies
Time Frame
Baseline, 3, 6, and 9 months
Other Pre-specified Outcome Measures:
Title
T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review
Description
Newly diagnosed T1D patients receiving 4T education and care monitored on a step-down cadence will H1a) achieve a 4-12 month change in HbA1c noninferior to that achieved under weekly review by a margin of 0.1 among 4T Pilot and 4T Study 1 patients and H1b) achieve a lower 4-12 month trajectory relative to external contemporary controls.
Time Frame
4-12 month trajectory in study 2
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 6 months-21 years of age. We intend to include all possible patients with the goal of maximizing generalizability of the results and 4T program. (NOTE: We will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.)
All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic
Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic
Individuals who agree to CGM data integration into the EMR for remote monitoring
Age: six months to < 21 years of age
Patient or guardian must own and operate an Apple compatible device (e.g., iPhone or iPod Touch) to allow for Dexcom app and Apple HealthKit integration and transmission to the hospital server-based remote monitoring system and EHR.
Dr Prahalad's LPCH Auxiliary Fund grant (in addition to the R18) has resources to support iPod Touch purchase for participants who do not have these.
o For the Exercise Ancillary study: 11 to < 21 years of age (the activity tracker is not validated for younger children) English and Spanish-Speaking (Study 2)
Exclusion Criteria:
Diabetes diagnosis other than T1D
Diagnosis of diabetes > one month prior to initial visit
Individuals with the intention of obtaining diabetes care at another clinic
Individuals who do not consent to CGM use, CGM data integration, remote monitoring
Individuals > 21 years of age
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David M Maahs, MD, PhD
Organizational Affiliation
Lucile Packard Children's Hospital; Stanford University, School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Franziska Katherine Bishop
City
Steamboat Springs
State/Province
Colorado
ZIP/Postal Code
80487
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study
We'll reach out to this number within 24 hrs